Norris Medicines — 360° view

Norris Medicines, a company in the Trading & Distributors industry, reported revenue of ₹0.66 crore and a net loss of ₹0.36 crore for the September 2026 quarter.

Norris Medicines (BSE: NORRIS) closed at ₹14.07 on 20 Nov 2026, down 13.7% over the past year. Its market capitalisation is ₹14 crore.

Share price
₹14.07 (20 Nov 2026)
Market cap
₹14 Cr (20 Nov 2026)
Revenue
₹1 Cr (September 2026 quarter)
Net profit
₹-0 Cr (September 2026 quarter)
ROCE
3.36% (FY26)
ROE
% (FY26)
Book value
₹-15.9 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹20.06 / ₹12.00 (20 Nov 2026)
1-year return
-13.7% (to 20 Nov 2026)
Sector
Services
Industry
Trading & Distributors
Symbol
BSE: NORRIS

Incorporated in 1990, Norris Medicines Ltd is a manufacturer of Injections and Medicinal formulations

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.